Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections
Authors:
- 11 July 2016
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 35 (10) , 1679-1689
Abstract
This study was aimed to determine the risk factors of Carbapenem-resistant Enterobacteriaceae (CRE) nosocomial infections and assess the clinical outcomes. A case-case–control design was used to compare two groups of case patients with control patients from March 2010 to November 2014 in China. Risk factors for the acquisition of CRE infections and clinical outcomes were analyzed by univariable and multivariable analysis. A total of 94 patients with CRE infections, 93 patients with Carbapenem-susceptible Enterobacteriaceae (CSE) infections, and 93 patients with organisms other than Enterobacteriaceae infections were enrolled in this study. Fifty-five isolates were detected as the carbapenemase gene. KPC-2 was the most common carbapenemase (65.5 %, 36/55), followed by NDM-1 (16.4 %, 9/55), IMP-4 (14.5 %, 8/55), NDM-5 (1.8 %, 1/55), and NDM-7 (1.8 %, 1/55). Multivariable analysis implicated previous use of third or fourth generation cephalosporins (odds ratio [OR], 4.557; 95 % confidence interval [CI], 1.971–10.539; P < 0.001) and carbapenems (OR, 4.058; 95 % CI, 1.753-9.397; P = 0.001) as independent risk factors associated with CRE infection. The in-hospital mortality of the CRE group was 57.4 %. In the population of CRE infection, presence of central venous catheters (OR, 4.464; 95 % CI, 1.332–14.925; P = 0.015) and receipt of immunosuppressors (OR, 7.246; 95 % CI, 1.217–43.478; P = 0.030) were independent risk factors for mortality. Appropriate definitive treatment (OR, 0.339; 95 % CI, 0.120–0.954; P = 0.040) was a protective factor for in-hospital death of CRE infection. Kaplan–Meier curves of the CRE group had the shortest survival time compared with the other two groups. Survival time of patients infected with Enterobacteriaceae with a high meropenem MIC (≥8 mg/L) was shorter than that of patients with a low meropenem MIC (2,4, and ≤ 1 mg/L). In conclusion, CRE nosocomial infections are associated with prior exposure to third or fourth generation cephalosporins and carbapenems. Patients infected with CRE had poor outcome and high mortality, especially high meropenem MIC (≥8 mg/L). Appropriate definitive treatment to CRE infections in the patient is essential.Keywords
Funding Information
- National Natural Science Foundation of China (81572036)
This publication has 35 references indexed in Scilit:
- Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa: clinical impact of bacterial virulence and strains on outcomeDiagnostic Microbiology and Infectious Disease, 2014
- Faculty Opinions recommendation of Vital signs: carbapenem-resistant Enterobacteriaceae.2014
- Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization: A case–case-control studyJournal of Infection and Chemotherapy, 2014
- Epidemiological Interpretation of Studies Examining the Effect of Antibiotic Usage on ResistanceClinical Microbiology Reviews, 2013
- A hospital-based matched case–control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infectionBMC Infectious Diseases, 2013
- Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?Clinical Microbiology and Infection, 2011
- Carbapenem-Resistant Enterobacteriaceae: Epidemiology and PreventionClinical Infectious Diseases, 2011
- Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UKJournal of Antimicrobial Chemotherapy, 2009
- Predictors of Carbapenem-Resistant Klebsiella pneumoniae Acquisition among Hospitalized Adults and Effect of Acquisition on MortalityAntimicrobial Agents and Chemotherapy, 2008
- The Case-Case-Control Study Design: Addressing the Limitations of Risk Factor Studies for Antimicrobial ResistanceInfection Control & Hospital Epidemiology, 2005